To improve efficiency and reduce administrative costs, healthcare providers, insurance companies, and governments are increasingly using integrated electronic health record (EHR) and picture archiving and communication systems (PACS) to manage patients' medical information. Reflecting the latest applications of PACS technology, PACS and Digital Medicine: Essential Principles and Modern Practice discusses the essential principles of PACS, EHR, and related technological advancements as well as practical issues concerning the implementation, operation, and maintenance of PACS and EHR systems. The book focuses on various components of PACS that use state-of-the-art technologies. The authors first present topics to consider prior to implementation, including design principles for PACS components and theory. They also cover post-installation quality control; security and privacy policies; maintenance, including upgrade/integration with other information systems; and governing standards. Each chapter includes an introduction to basic concepts and principles relevant to the topics, before exploring challenges that PACS users may encounter in daily work. Discussions are supplemented with more than 130 illustrations, along with case studies of implementation in two organizations. A useful guide and broad overview of the field, this book presents key principles and practical steps for PACS and EHR implementations and maintenance. Although the technology and standards of healthcare IT will evolve over time, the theory and practical advice found in this text will remain pertinent in the future.

Lymphatic mapping techniques have proven to be useful to the early detection and safe treatment of endometrial and cervical cancers; however, the techniques have much of value to offer for breast cancer also and particularly for vulvar cancer, where there has been an explosion of interest and research. In the new edition of Clinical Lymphatic Mapping of Gynecologic Cancers, the techniques are fully explained, with consideration of the latest developments and technologies.

This textbook is a clear and accessible introduction to the scientific and clinical aspects of the creation, development and administration of drugs or drug regimens used in the treatment of cancer. Unique in its approach, this book enables the student to gain an understanding of the pathological, physiological and molecular processes governing malignancy, whilst also introducing the role of health professionals and scientists in the research and treatment of cancer. The book consolidates all the essential information necessary for a full understanding of cancer chemotherapy, providing an informative, inexpensive and up-to-date coverage of the subject aimed at an undergraduate level readership. Key Features:* Incorporates numerous diagrams, tables and illustrations to aid understanding.* Examines key pharmacological and pharmaceutical issues such as dosing, toxicity and preparation of anti-cancer drugs.* Includes a key chapter of practice essay questions to ease revision.* Comprehensive coverage of drugs currently in pre-clinical and clinical development.* An indispensable text for undergraduate students studying pharmacy and medicine as well as those doing courses such as molecular biology, biomedical sciences and pharmacology which cover aspects of oncology.

Filling a gap in the literature, this guide provides expert recommendations and research on carcinoma of an unknown primary site (CUP). Covering the identification, diagnosis, and management of CUP with illustrative and reader-friendly clinical case examples, this reference helps physicians treat patients whose primary cancer site is difficult to locate and assess.

Recent developments with novel systemic drugs, palliative surgical techniques and diagnostic imaging have given hope for the treatment of patients whose breast cancer has spread beyond its primary tumour. Written by a team from leading cancer centers in Europe, including the UK's Royal Marsden Hospital, the Handbook of Metastatic Breast Cancer, Second Edition provides advanced scientific information and guidance on clinical problems associated with metastatic breast cancer.

A behind-the-scenes look inside three key trials involving Monsanto's weed killer Roundup, cancer, and the search for justice—written by an expert witness medical oncologist who lived it all. For years, Monsanto declared that their product Roundup, the world's most widely used weed killer, was safe. But that all changed in 2015, when the International Agency for Research on Cancer (IARC) analyzed data from scientific studies and concluded that glyphosate, the active ingredient in Roundup, is probably carcinogenic. The Environmental Protection Agency (EPA) disagreed, other regulatory agencies got involved, and scientists clamored to understand the link between glyphosate and cancer. Toxic Exposure tells the true story of numerous patients who developed non-Hodgkin lymphoma, a form of cancer, after using Roundup and their ensuing trials against Monsanto (now owned by Bayer, one of the largest agrochemical companies in the world). Written by Chadi Nabhan, MD, MBA, a cancer specialist, this is the only book written by an expert physician witness who testified in the first three trials against Monsanto. Dr. Nabhan takes the reader behind the scenes of these pivotal trials, explaining key features of the cases, including how Monsanto downplayed the IARC's scientific conclusions, may have worked to change how the EPA classified glyphosate, and conducted extensive PR campaigns designed to minimize the public's perception of the negative health effects of its product. He also provides details about the other expert witnesses who reviewed the evidence, analyzed the science, and stood up to this agricultural behemoth in the courtroom. Dr. Nabhan tells the inside story of corporate influence, courtroom drama, legal discourse, monumental verdicts, and the ensuing media frenzy surrounding this massive uncovering of the truth and the years of scientific and legal work that led up to it.

Biomathematical Problems in Optimization of Cancer Radiotherapy provides insight into the role of cell population heterogeneity in the optimal control of fractionated irradiation of tumors. The book emphasizes the mathematical modeling aspect of the problem and presents the state of the art in the stochastic description of irradiated cell survival. Some of the results are of general theoretical interest and can be applied to other areas of optimal control methodology. Detailed explanations of all mathematical statements are provided throughout the text. The book is excellent for biomathematicians, radiotherapists, oncologists, health physicists, and other researchers and students interested in the topic.

Reflecting the past 20 years of intense research in radioimmunotherapy, this timely reference surveys an expansive breadth of topics on the evolving developments in radiation therapy. Placed in the context of advances in cancer treatment, chapters progress systematically from basic principles and properties of radionuclides to detailed summaries of current cancer therapy. With contributions from nearly 50 international experts and containing over 1300 literature references, drawings, photographs, tables, and equations, Radioimmunotherapy of Cancer is an invaluable and indispensable reference for physicians in nuclear medicine and medical physicists; oncologists, radiologists, radiochemists, and radiopharmacists; immunologists, pulmonologists, and cancer researchers; pharmacologists and drug delivery pharmaceutical chemists; and upper-level undergraduate, graduate, and medical school students in these disciplines.

Outlining the best means of infection management and emphasizing early recognition and identification of pathogens, this trailblazing volume pinpoints the distinct immunodeficiencies related to specific malignancies that result in predictable opportunistic infections-containing accessible reviews of the latest scientific research, reports from the forefront of clinical practice, and copious illustrations and tables to be of maximal benefit to the reader.

Understand Quantitative Radiobiology from a Radiation Biophysics Perspective In the field of radiobiology, the linear-quadratic (LQ) equation has become the standard for defining radiation-induced cell killing. Radiotherapy Treatment Planning: Linear-Quadratic Radiobiology describes tumor cell inactivation from a radiation physics perspective and offers appropriate LQ parameters for modeling tumor and normal tissue responses. Explore the Latest Cell Killing Numbers for Defining Iso-Effective Cancer Treatments The book compiles radiation mechanism information from biophysical publications of the past 50 years, addressing how ionizing radiation produces the killing of stem cells in human tumors. It presents several physical and chemical parameters that can modulate the radiation response of clonogenic cells in tumors. The authors describe the use of the LQ model in basic radiation mechanism studies with cells of relatively homogeneous radiation response and then extend the model to the fitting of survival data generated with heterogeneous cell populations (tumors). They briefly discuss how to use the LQ model for predicting tumor (local) control probability (TCP) and normal tissue complication probability (NTCP). The book also examines potential molecular targets related to alpha- and beta-inactivation and gives suggestions for further molecular characterizations of these two independent processes. Develop Efficacious, Patient-Friendly Treatments at Reduced Costs Focusing on quantitative radiobiology in LQ formulation, this book assists medical physicists and radiation oncologists in identifying improved cancer treatments. It also encourages investigators to translate potentially improved radiotherapy schedules based on TCP and NTCP modeling into actual patient benefit.

In the past, disease pattern mapping depended on census tracts based on political units, such as states and counties. However, with the advent of geographic information systems (GIS), researchers can now achieve a new level of precision and flexibility in geographic locating. This emerging technology allows the mapping of many different kinds of geographies, including disease rates in relation to pollution sources. Geocoding Health Data presents a state-of-the-art discussion on the current technical and administrative developments in geographic information science. In particular, it discusses how geocoded residential addresses can be used to examine the spatial patterns of cancer incidence, staging, survival, and mortality. The book begins with an introduction of various codes and their uses, including census geographic, health area, and street level codes. It goes on to describe the specific application of geocodes to cancer, detailing methods, materials, and technical issues. The text illustrates how to compile data maps for analysis and addresses issues, such as mismatch correction and data quality. It describes the current state of geocoding practices and discusses the use of individually geocoded cancer incidences in spatial epidemiology, distance estimation and spatial accessibilities, and tips for handling non-geocoded cases. Special consideration is given to privacy and confidentiality issues by focusing on disclosure limitation methods. With recent disease outbreaks and escalating concerns about bioterrorism, interest in the application of GIS to individual data is growing. The fundamental concepts presented by this book are of great value to anyone trying to understand the causes, prevention, and control of cancer as well as a variety of other diseases.

Based on a Tumor Immunology Symposium held in Pittsburgh, this work provides comprehensive coverage of the most important aspects of tumor immunology. It reveals novel approaches to the immunotherapy of cancer and presents complex issues in an accessible manner.

Radiation dosimetry has made great progress in the last decade, mainly because radiation therapy is much more widely used. Since the first edition, many new developments have been made in the basic methods for dosimetry, i.e. ionization chambers, TLD, chemical dosimeters, and photographic films. Radiation Dosimetry: Instrumentation and Methods, Second Edition brings to the reader these latest developments. Written at a high level for medical physicists, engineers, and advanced dosimetrists, it concentrates only on evolvement during the last decade, relying on the first edition to provide the basics. This is an excellent complement to the first edition.

Based on a conference on Oxidative Stress and Redox Regulation, held at the Pasteur Institute, Paris, this work examines fundamental, chemical, biological and medical studies of free radicals on different targets and the consequences of their reactivity. It covers the chemistry and biochemistry of free radicals, free radicals as second messengers that group the activation of transcription factors and enzymes, the importance of the antioxidant system in cell metabolism regulation, and the role of free radicals and antioxidants in disease management. The editors of this work are three of the most respected pioneers in the field. Dr. Montagnier is credited as the discoverer of HIV.

Remarkable advances have occurred since the Series 3 Fascicle published in 1995 with paradigm shifts in every dimension of our understanding of lung tumors including clinical, radiologic, histopathologic, cytopathologic, immunohistochemical, molecular and therapeutic aspects. The molecular revolution leading to effective targeted therapies and breakthroughs in immunotherapy for lung cancer have led to novel approaches incorporating the concept of personalized medicine for patients who historically had little hope. These advances have strengthened the place of pathologists to play a central role in the multidisciplinary team that is now needed to properly diagnose and manage lung cancer patients.

Award-winning author, Samuel S. Epstein, M.D., whose 1978 book ""The Politics of Cancer"" shook the political establishment by showing how the federal government had been corrupted by industrial polluters, has written a book that is sure to be of equal consequence. ""Cancer-Gate: How to Win the Losing Cancer War"" is a groundbreaking new book. It warns that, contrary to three decades of promises, we are losing the winnable war against cancer, and that the hand-in-glove generals of the federal National Cancer Institute (NCI) and the private ""nonprofit"" American Cancer Society (ACS) have betrayed us.These institutions, Epstein alleges, have spent tens of billions of taxpayer and charity dollars primarily targeting silver-bullet cures, strategies that have largely failed, while virtually ignoring strategies for preventing cancer in the first place. As a result, cancer rates have escalated to epidemic proportions, now striking nearly one in every two men, and more than one in every three women. This translates into approximately 50 percent more cancer in men, and 20 percent more cancer in women over the course of just one generation.

Scientists have reached a critical point in the development of new therapies for prostate cancer. The information gleaned from the Human Genome Project, alongside the emergence of new technologies for the use of genetic data has expanded the physician's understanding of disease progression and widened his armamentarium for prostate cancer prevention and control. This expertly-written reference thoroughly analyzes the scientific principles and methodologies behind the most recent translational therapies and provides the necessary context, data, and studies for practitioners to select appropriate candidates for treatment and effectively apply new therapies in clinical practice.

Appraising cancer as a major medical market in the 2010s, Wall Street investors placed their bets on single-technology treatment facilities costing $100-$300 million each. Critics inside medicine called the widely-publicized proton-center boom "crazy medicine and unsustainable public policy." There was no valid evidence, they claimed, that proton beams were more effective than less costly alternatives. But developers expected insurance to cover their centers' staggeringly high costs and debts. Was speculation like this new to health care? Cancer, Radiation Therapy, and the Market shows how the radiation therapy specialty in the United States (later called radiation oncology) coevolved with its device industry throughout the twentieth-century. Academic engineers and physicians acquired financing to develop increasingly powerful radiation devices, initiated companies to manufacture the devices competitively, and designed hospital and freestanding procedure units to utilize them. In the process, they incorporated market strategies into medical organization and practice. Although palliative benefits and striking tumor reductions fueled hopes of curing cancer, scientific research all too often found serious patient harm and disappointing beneficial impact on cancer survival. This thoroughly documented and provocative inquiry concludes that public health policy needs to re-evaluate market-driven high-tech medicine and build evidence-based health care systems.

Developing an effective computer-aided diagnosis (CAD) system for lung cancer is of great clinical importance and can significantly increase the patient's chance for survival. For this reason, CAD systems for lung cancer have been investigated in a large number of research studies. A typical CAD system for lung cancer diagnosis is composed of four main processing steps: segmentation of the lung fields, detection of nodules inside the lung fields, segmentation of the detected nodules, and diagnosis of the nodules as benign or malignant. This book overviews the current state-of-the-art techniques that have been developed to implement each of these CAD processing steps. Overviews the latest state-of-the-art diagnostic CAD systems for lung cancer imaging and diagnosis Offers detailed coverage of 3D and 4D image segmentation Illustrates unique fully automated detection systems coupled with 4D Computed Tomography (CT) Written by authors who are world-class researchers in the biomedical imaging sciences Includes extensive references at the end of each chapter to enhance further study Ayman El-Baz is a professor, university scholar, and chair of the Bioengineering Department at the University of Louisville, Louisville, Kentucky. He earned his bachelor's and master's degrees in electrical engineering in 1997 and 2001, respectively. He earned his doctoral degree in electrical engineering from the University of Louisville in 2006. In 2009, he was named a Coulter Fellow for his contributions to the field of biomedical translational research. He has 17 years of hands-on experience in the fields of bio-imaging modeling and noninvasive computer-assisted diagnosis systems. He has authored or coauthored more than 500 technical articles (132 journals, 23 books, 57 book chapters, 211 refereed-conference papers, 137 abstracts, and 27 U.S. patents and disclosures). Jasjit S. Suri is an innovator, scientist, a visionary, an industrialist, and an internationally known world leader in biomedical engineering. He has spent over 25 years in the field of biomedical engineering/devices and its management. He received his doctorate from the University of Washington, Seattle, and his business management sciences degree from Weatherhead School of Management, Case Western Reserve University, Cleveland, Ohio. He was awarded the President's Gold Medal in 1980 and named a Fellow of the American Institute of Medical and Biological Engineering for his outstanding contributions in 2004. In 2018, he was awarded the Marquis Life Time Achievement Award for his outstanding contributions and dedication to medical imaging and its management.

There is an increasing need for educational resources for statisticians and investigators. Reflecting this, the goal of this book is to provide readers with a sound foundation in the statistical design, conduct, and analysis of clinical trials. Furthermore, it is intended as a guide for statisticians and investigators with minimal clinical trial experience who are interested in pursuing a career in this area. The advancement in genetic and molecular technologies have revolutionized drug development. In recent years, clinical trials have become increasingly sophisticated as they incorporate genomic studies, and efficient designs (such as basket and umbrella trials) have permeated the field. This book offers the requisite background and expert guidance for the innovative statistical design and analysis of clinical trials in oncology. Key Features: Cutting-edge topics with appropriate technical background Built around case studies which give the work a "hands-on" approach Real examples of flaws in previously reported clinical trials and how to avoid them Access to statistical code on the book's website Chapters written by internationally recognized statisticians from academia and pharmaceutical companies Carefully edited to ensure consistency in style, level, and approach Topics covered include innovating phase I and II designs, trials in immune-oncology and rare diseases, among many others

The growing number of cancer survivors presents a new challenge to generalists and specialists involved in their care. Prior cancer treatments may compound known comorbidities or contribute to future health risks. The ultimate success of cancer treatments ultimately depends on the meticulous management of post-cancer care, and this requires a clinical workforce that is engaged and ready. Cancer survivorship has now become recognized as an independent field of research and clinical practice. This new concise guide is intended for cancer clinicians as well as generalists and specialists who meet cancer survivors in their practices for routine check-ups or specialized consultations. With an expanding population known to have complex medical, psychosocial and emotional needs, we hope this book sparks interest and provides answers for those involved in their care.

On-treatment verification imaging has developed rapidly in recent years and is now at the heart of image-guided radiation therapy (IGRT) and all aspects of radiotherapy planning and treatment delivery. This is the first book dedicated to just this important topic, which is written in an accessible manner for undergraduate and graduate therapeutic radiography (radiation therapist) students and trainee medical physicists and clinicians. The later sections of the book will also help established medical physicists, therapeutic radiographers, and radiation therapists familiarise themselves with developing and cutting-edge techniques in IGRT. Features: Clinically focused and internationally applicable; covering a wide range of topics related to on-treatment verification imaging for the study of IGRT Accompanied by a library of electronic teaching and assessment resources for further learning and understanding Authored by experts in the field with over 18 years' experience of pioneering the original forms of on-treatment verification imaging in radiotherapy (electronic portal imaging) in clinical practice, as well as substantial experience of teaching the techniques to trainees

This book offers a conceptual explanation of the interrelationships that exist between the stages in the progression of initiated epithelial cells in culture compared with the diverse tissue of organs and the progression of tumors from different organ sites. The fate of the modification of adducts is discussed at the molecular level. The role that modifications in hot spots in oncogenes and supressor genes play at the molecular level and how these molecular modifications can lead to an explanation of molecular control in the formation of tumor phenotypes is also examined. Researchers in cell biology and toxicology, applied pharmacology, carcinogenesis, teratogenesis, mutagenesis, and molecular toxicology will find the book useful, interesting reading.